cyc 202 has been researched along with Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunt, KK; Keyomarsi, K; Lambert, DH; Lambert, LA; Meijer, L; Mills, GB; Qiao, N | 1 |
| Coley, HM; Kokkinos, MI; Shotton, CF; Thomas, H | 1 |
2 other study(ies) available for cyc 202 and Sarcoma
| Article | Year |
|---|---|
Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cytotoxins; Doxorubicin; Drug Synergism; G2 Phase; Humans; Models, Biological; Purines; Roscovitine; Sarcoma; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2008 |
The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Protein Kinase Inhibitors; Purines; RNA, Messenger; Roscovitine; Sarcoma; Transcriptional Activation; Uterine Neoplasms | 2007 |